Lupin Limited

LUPIN.NS

Mumbai, India· Est. 1968

lupin.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

LUPIN.NS · Stock Price

INR 2,442.90+428.10 (+21.25%)

Market Cap: $11.9B

Historical price data

Market Cap: $11.9BPipeline: 1 drug (1 Phase 3)Patents: 20Founded: 1968Employees: 16,000+HQ: Mumbai, India

Sector Ranking#10 in Small Molecule Drugs #4 in Drug Delivery & Formulation

Overview

Lupin Limited is a multinational pharmaceutical leader with a mission to catalyze treatments that transform hope into healing, driven by science and a patient-first mindset. The company has achieved global scale with operations in over 100 countries, 15+ manufacturing facilities, and a diversified business spanning generics, complex formulations, APIs, and emerging adjacencies in diagnostics and digital health. Its strategy integrates vertical integration, R&D in complex generics and biosimilars, and expansion into holistic healthcare solutions to drive sustainable growth in both developed and emerging markets.

CardiovascularDiabetologyAsthma/RespiratoryCentral Nervous SystemGastrointestinalAnti-infectivesPain Management/NSAIDs

Technology Platform

Integrated platform focused on complex generic development (inhalation, modified-release, injectables), API synthesis, and digital health solutions for chronic disease management.

Pipeline

1 drug in pipeline1 in Phase 3

Drug	Indication	Stage	Watch
Escitalopram + Bupropion XL	Bipolar I Disorder	Phase 3

Funding History

IPOUndisclosedUndisclosedJun 15, 2000

FDA Approved Drugs

BRIVARACETAMANDAFeb 23, 2026

ARMLUPEGBLANov 28, 2025

RIVAROXABANANDASep 25, 2025

Opportunities

Significant opportunities exist in the global complex generics and biosimilars market, driven by patent expiries.

Expansion into adjacent healthcare services (diagnostics, digital health) offers new growth vectors and deeper patient engagement.

The rising burden of chronic diseases in emerging markets aligns perfectly with Lupin's therapeutic and geographic strengths.

Risk Factors

Key risks include regulatory compliance challenges at manufacturing facilities, intense pricing pressure and competition in core generics markets, and potential delays or failures in the complex generic pipeline and patent litigation.

Successful integration and scaling of non-pharma adjacencies also present execution risks.

Competitive Landscape

Lupin competes with large Indian generics firms (Sun Pharma, Dr. Reddy's) and global giants (Teva, Viatris) in generics, and a narrower set of players in complex generics. In adjacencies, it faces specialized competitors in diagnostics and digital health. Its vertical integration and expertise in inhalation technology are key differentiators.